Xiangdong Cheng, Zhiyuan Xu, Can Hu. "Perioperative tislelizumab plus chemotherapy versus chemotherapy in MHC-II positive/MHC-II negative locally advanced GC/GEJC: A prospective, randomized, open-label, biomarker-driven, phase 2 trial.." Journal of Clinical Oncology, 2026. doi:10.1200/jco.2026.44.16_suppl.2513